1e
19
1
49
2
2
18
1b
1d
18
37
49
1d
2 29
1d
25
Alice S. Chen-Plotkin, MD
78
49
Parker Family Professor of Neurology
28
78
3
60
Attending Neurologist, Hospital of the University of Pennsylvania
8b
Founding Director, Molecular Integration in Neurological Diagnosis (MIND) Initiative
11
Department: Neurology
4
1
23
1f
Graduate Group Affiliations
8
b
-
41
- Bioengineering 6b
- Cell and Molecular Biology 64
- Neuroscience e
1d
46
Contact information
58
4
3
3
3
2
29
58
Hospital of the University of Pennsylvania
37 150 Johnson Pavilion
Philadelphia, PA 19104
26
37 150 Johnson Pavilion
Philadelphia, PA 19104
2e
Office: 215-829-6500
3e Lab: 215-746-8191
18
9f
12
3e Lab: 215-746-8191
18
Links
70 Chen-Plotkin lab website
bb Website for the Molecular Integration in Neurological Diagnosis (MIND) Initiative, directed by Alice Chen-Plotkin
c
4
b
1f
70 Chen-Plotkin lab website
bb Website for the Molecular Integration in Neurological Diagnosis (MIND) Initiative, directed by Alice Chen-Plotkin
c
13
Education:
21 7 AB 14 (English) c
32 Harvard-Radcliffe College, 1996.
21 8 MSc 14 (Biology) c
2d University of Oxford, 1998.
21 7 MD c
2f Harvard Medical School, 2003.
c
3
3
3
3
8d
Permanent link21 7 AB 14 (English) c
32 Harvard-Radcliffe College, 1996.
21 8 MSc 14 (Biology) c
2d University of Oxford, 1998.
21 7 MD c
2f Harvard Medical School, 2003.
c
2 29
21
1e
1d
24
5e
8
23b Our general approach is to use unbiased genomic- or proteomic-scale screens in human-derived materials to generate leads, which are then followed mechanistically in relevant systems including neuronal culture and in vivo animal models. The pace of technology development is allowing us to acquire more data, faster, than ever before, but this does not always translate into biological understanding. We believe that to unlock the true potential of leads generated in this way, computational methods must work hand-in-hand with bench-based manipulative experiments.
65
1a 29
27
Description of Research Expertise
ac The over-arching goal of our research is to better understand the mechanisms of neurodegenerative disease in order to intervene in these disease processes.8
23b Our general approach is to use unbiased genomic- or proteomic-scale screens in human-derived materials to generate leads, which are then followed mechanistically in relevant systems including neuronal culture and in vivo animal models. The pace of technology development is allowing us to acquire more data, faster, than ever before, but this does not always translate into biological understanding. We believe that to unlock the true potential of leads generated in this way, computational methods must work hand-in-hand with bench-based manipulative experiments.
65
Description of Clinical Expertise
22 Movement disorders1a 29
23
157 Shen J, Amari N, Zack R, Skrinak RT, Unger TL, Posavi M, Tropea TF, Xie SX, Van Deerlin VM, Dewey RB Jr, Weintraub D, Trojanowski JQ, Chen-Plotkin AS.: Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease. Ann Neurol 92(2): 255-269, August 2022.
15a Weintraub D, Posavi M, Fontanillas P, Tropea TF, Mamikonyan E, Suh E, Trojanowski JQ, Cannon P, Van Deerlin VM; 23andMe Research Team, Chen-Plotkin AS.: Genetic prediction of impulse control disorders in Parkinson's disease. Ann Clin Transl Neurol 9(7): 936-949, July 2022.
df Carceles-Cordon M, Weintraub D, Chen-Plotkin AS.: Cognitive heterogeneity in Parkinson's disease: A mechanistic view. Neuron 111: 1531-1546, May 2023.
2c
7
1d
1f
Selected Publications
1aa Diaz-Ortiz ME, Seo Y, Posavi M, Carceles Cordon M, Clark E, Jain N, Charan R, Gallagher MD, Unger TL, Amari N, Skrinak RT, Davila-Rivera R, Brody EM, Han N, Zack R, Van Deerlin VM, Tropea TF, Luk KC, Lee EB, Weintraub D, Chen-Plotkin AS.: GPNMB confers risk for Parkinson's disease through interaction with α-synuclein. Science 377: eabk0637, Aug 2022.157 Shen J, Amari N, Zack R, Skrinak RT, Unger TL, Posavi M, Tropea TF, Xie SX, Van Deerlin VM, Dewey RB Jr, Weintraub D, Trojanowski JQ, Chen-Plotkin AS.: Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease. Ann Neurol 92(2): 255-269, August 2022.
15a Weintraub D, Posavi M, Fontanillas P, Tropea TF, Mamikonyan E, Suh E, Trojanowski JQ, Cannon P, Van Deerlin VM; 23andMe Research Team, Chen-Plotkin AS.: Genetic prediction of impulse control disorders in Parkinson's disease. Ann Clin Transl Neurol 9(7): 936-949, July 2022.
df Carceles-Cordon M, Weintraub D, Chen-Plotkin AS.: Cognitive heterogeneity in Parkinson's disease: A mechanistic view. Neuron 111: 1531-1546, May 2023.
2c